Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Diabetes, Obesity and Metabolism · 2025-05 · 27 (5) · 2540-2551
DOI: 10.1111/dom.16253 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.03.2025. Verfasst von Weijun Gu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight, Anti-Obesity Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Aim
To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. Materials and Methods In STEP 7 (NCT04251156), a double‐blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once‐weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced‐calorie diet and increased physical activity. This prespecified analysis evaluated Chinese participants in STEP 7. The primary endpoints were percentage change in body weight from baseline to Week 44 and the proportion of participants who achieved ≥5% reduction in body weight from baseline.
Results
Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo. Estimated change in mean body weight from baseline to Week 44 was −11.8% with semaglutide 2.4 mg versus −3.5% with placebo (estimated treatment difference −8.3%; 95% confidence interval [CI] –10.2, −6.4; p < 0.0001). At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001. Adverse events were reported by 92.3% of semaglutide‐treated participants and 82.9% of placebo‐treated participants, the most common of which were gastrointestinal disorders (126/195, 64.6% vs. 35/105, 33.3%).
Conclusions
These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Endocrinology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
- Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China.
ORCID-Profile: Weijun Gu, Guoyue Yuan, Yiming Mu
Förderung
- Novo Nordisk A/S
Zitieren
APA
Gu, W., Lu, Y., Ye, X., Yuan, G., Liu, D., Shen, Z., Zu, N., & Mu, Y. (2025). Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial. Diabetes, Obesity and Metabolism, 27(5), 2540-2551. https://doi.org/10.1111/dom.16253
Vancouver
Gu W, Lu Y, Ye X, Yuan G, Liu D, Shen Z, et al. Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial. Diabetes, Obesity and Metabolism. 2025;27(5):2540-2551. doi:10.1111/dom.16253
BibTeX
@article{Gu2025,
author = {Gu, Weijun and Lu, Yibing and Ye, Xinhua and Yuan, Guoyue and Liu, Dongmei and Shen, Zewei and Zu, Ning and Mu, Yiming},
title = {Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {5},
pages = {2540--2551},
doi = {10.1111/dom.16253}
}
EUVIMED